Method for determining human immunodeficiciency virus type 1 (HIV-1) hypersusceptibility to the protease inhibitor amprenavir
US7553618B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 1, 2003 |
| Grant date | Jun 30, 2009 |
| Priority date | — |
| Expiry date | Sep 1, 2025 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N33/56988
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention provides an approach for developing an algorithm for determining the effectiveness of anti-viral drugs based on a comprehensive analysis of paired phenotypic and genotypic data guided by phenotypic clinical cut-offs. In one aspect, the algorithm allows one to provide a patient with effective treatment. It helps predict whether an infected individual will respond to treatment with an anti-viral compound, thereby allowing an effective treatment regimen to be designed without subjecting the patient to unnecessary side effects. Also, by avoiding the administration of ineffective drugs, considerable time and money is saved.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.